All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-aggregation Inhibition: Persistence with treatment and cardiovascular Events in Real world (PIPER) study

Podobne zapisy

• Long-Term Use of Antiplatelet Therapy in Real-World Patients with Acute Myocardial Infarction: Insights from the PIPER Study
  od: Degli Esposti, Luca, i wsp.
  Wydane: (2018)
• Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis
  od: Perrone, Valentina, i wsp.
  Wydane: (2020)
• Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study
  od: Perrone, Valentina, i wsp.
  Wydane: (2016)
• Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ‘real-world’ retrospective cohort study
  od: Degli Esposti, Luca, i wsp.
  Wydane: (2016)
• Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
  od: Perrone, Valentina, i wsp.
  Wydane: (2016)